<http://schema.org/articleBody>
"<p>Along with rolling out the (five-in-one vaccine to check  pneumonia as planned, the union health ministry will launch an impact study in  one high-mortality state before deciding on introducing pneumococcal conjugate  vaccine as part of the India&rsquo;s national immunization program. </p><br /><p>The National Technical Advisory Group, India, the highest body  to advise the government on introducing any vaccine, had recommended for an  impact study on the seven-valent pneumococcal vaccine (PCV 7) in one state as  early as possible. The government, which is yet to finalize the state for the  study, will make a decision on introducing PCV based on the outcome of the  study, sources said.</p><br /><p>Taking into consideration the existing data and prevalence of  pneumonia among children, the NTAGI had recommended the national roll out of Hib  vaccine by 2012 as a multi-dose liquid pentavalent vaccine (DPT-Hep B-Hib) and  the government is going ahead with the plan to introduce the same in 10 states  next year. </p><br /><p>Haemophilus influenza type b (Hib) is one of the two bacteria  causing pneumonia and meningitis. Experts in the field have called for the  introduction of PCV as the follow-up to this Hib because it immunizes children  against pneumonia and other diseases caused by Streptococcus pneumoniae. </p><br /><p>The Indian Association of Pediatrics: Committee on Immunization  has recommended for inclusion of pneumococcal vaccines in the routine  immunization schedule, considering the high mortality caused by this disease in  children in the country. </p>"^^<http://www.w3.org/2001/XMLSchema#string>
<http://vaccinenewsdaily.com/stories/510530588-india-s-health-ministry-to-initiate-impact-study-on-pneumococcal-conjugate-vaccine>